Latest news with #ImmunoGenesis
Globe and Mail
3 days ago
- Business
- Globe and Mail
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON , May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/ 1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025 . This Phase 1a/ 1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b . The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling. "This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer , PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results." "We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow , President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need." ASCO Poster Presentation Title: A Phase 1a/ 1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors. Abstract: TS2686 | Poster Bd #: 324a Track: Developmental Therapeutics—Immunotherapy Location: Hall A -Posters and Exhibits | On Demand Time: June 2, 2025 , 1:30 PM – 4:30 PM CDT About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. Contact ImmunoGenesis
Cision Canada
3 days ago
- Business
- Cision Canada
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, May 30, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/1b clinical trial of IMGS-001 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 30 to June 3, 2025. This Phase 1a/1b first-in-human, open-label, multicenter study (NCT06014502) includes a dose escalation and an expansion portion to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of IMGS-001 in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. The study will enroll approximately 25 patients in Phase 1a and up to 250 in Phase 1b. The first three of five planned dose cohorts have completed without any dose limiting toxicities (DLTs), with cohort 4 (10 mg/kg) now enrolling. "This clinical trial is an important first step to understand how IMGS-001 may potentially remove immunosuppressive cells while improving PD-1 pathway blockade to treat otherwise immunoresistant tumors that represent a significant unmet medical need," stated Charles Schweizer, PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "We are pleased to discuss the study plan and progress at this important conference as we look ahead to sharing results." "We are encouraged by the early performance of IMGS-001 as we proceed with Phase 1 dose escalation in patients with a variety of advanced solid tumors," said James Barlow, President and CEO of ImmunoGenesis. "Initial low doses administered to date have been well-tolerated with no dose-limiting toxicities, and we are seeing promising early signs of anti-tumor activity in patients who have failed prior treatments. IMGS-001 has the potential to be a foundational therapy for immune-excluded tumors, addressing a major unmet need." ASCO Poster Presentation Title: A Phase 1a/1b study to evaluate the safety, tolerability, Pharmakokinetics, and anti-tumor activity of IMGS-001 in Patients with relapsed or refractory advanced solid tumors. Abstract: TS2686 | Poster Bd #: 324a Track: Developmental Therapeutics—Immunotherapy Location: Hall A -Posters and Exhibits | On Demand Time: June 2, 2025, 1:30 PM – 4:30 PM CDT About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001, the lead program at ImmunoGenesis, is a PD-L1/PD-L2 dual-specific monoclonal antibody with engineered cytotoxic effector function. IMGS-001 is the first molecule in clinical testing to target PD-L2 in addition to PD-L1, potentially improving blockade of the PD-1 pathway. The engineered effector function may enable IMGS-001 to eliminate immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove higher response rates in head-to-head studies compared to currently available immunotherapies. IMGS-001 may provide a new foundational therapy with its innovative multitasking mechanism of superior blockade and cytotoxic effector function. IMGS-001 is being developed with support from the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094 as well as an investment from the Cancer Focus Fund, LP. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc.
Globe and Mail
19-05-2025
- Business
- Globe and Mail
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Soft Tissue Sarcoma Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Soft Tissue Sarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Soft Tissue Sarcoma Pipeline Outlook Key Takeaways from the Soft Tissue Sarcoma Marketed and Pipeline Drugs Report In May 2025, Adcendo ApS announced a Phase 1/2 study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma. In May 2025, ImmunoGenesis conducted a study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies. In May 2025, Epizyme Inc. organized a study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. DelveInsight's Soft Tissue Sarcoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Soft Tissue Sarcoma treatment. The leading Soft Tissue Sarcoma Companies such as Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others. Promising Soft Tissue Sarcoma Pipeline Therapies such as Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others. Stay ahead with the most recent pipeline outlook for Soft Tissue Sarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Soft Tissue Sarcoma Treatment Drugs Soft Tissue Sarcoma Emerging Drugs Profile Fibronum + Doxorubicin: Philogen S.p.A. Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma. Chiauranib: Chipscreen Biosciences, Ltd Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma. LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma. The Soft Tissue Sarcoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment. Soft Tissue Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market Explore groundbreaking therapies and clinical trials in the Soft Tissue Sarcoma Pipeline. Access DelveInsight's detailed report now! @ New Soft Tissue Sarcoma Drugs Soft Tissue Sarcoma Companies Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others. Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Soft Tissue Sarcoma Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Bronchiectasis Treatment. Learn about new Soft Tissue Sarcoma Marketed and Drugs Developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers Scope of the Soft Tissue Sarcoma Pipeline Report Coverage- Global Soft Tissue Sarcoma Companies- Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others. Soft Tissue Sarcoma Pipeline Therapies- Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others. Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Soft Tissue Sarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Soft Tissue Sarcoma Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Soft Tissue Sarcoma: Overview Pipeline Therapeutics Therapeutic Assessment Soft Tissue Sarcoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Fibronum + Doxorubicin: Philogen S.p.A. Drug profiles in the detailed report….. Mid Stage Products (Phase II) Chiauranib: Chipscreen Biosciences, Ltd Drug profiles in the detailed report….. Early Stage Products (Phase I/II) LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Soft Tissue Sarcoma Key Companies Soft Tissue Sarcoma Key Products Soft Tissue Sarcoma- Unmet Needs Soft Tissue Sarcoma- Market Drivers and Barriers Soft Tissue Sarcoma- Future Perspectives and Conclusion Soft Tissue Sarcoma Analyst Views Soft Tissue Sarcoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
07-03-2025
- Health
- Yahoo
ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent
ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the hypoxia reversal agent, in conjunction with Balstilimab and Zalifrelimab, for treating adults with certain cancer types. The subject was dosed at the University of Texas MD Anderson Cancer Center in Houston, US. The open-label trial will focus on adults with locally advanced or metastatic castration-resistant prostate cancer, human papillomavirus-(HPV) negative squamous cell carcinoma of the head and neck (SCCHN), and pancreatic cancer. It comprises a dose escalation and expansion part to assess the pharmacokinetics, efficacy, anti-tumour activity, and safety of the combination. ImmunoGenesis Clinical Development senior vice-president Dr Charles Schweizer said: 'This trial marks an exciting step forward in addressing one of the key challenges in cancer immunotherapy. Hypoxia limits T-cell infiltration and suppresses immune responses, especially in prostate, pancreatic, and head and neck cancers. 'By reversing hypoxia, IMGS-101 may restore T-cell access to tumours, enhancing the effectiveness of checkpoint inhibitors and potentially transforming outcomes in these hard-to-treat cancers.' Also referred to as Evofosfamide, IMGS-101 is stated to be a 2-nitroimidazole prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) that was initially developed as a hypoxia-activated prodrug. Dr Michael Curran of MD Anderson and the founder of ImmunoGenesis demonstrated in his lab that IMGS-101 has a unique ability to overcome one of the most significant immunosuppressive barriers by reversing hypoxia. The therapy is claimed to have 'restored' the function of T-cells in pre-clinical models and during a Phase I study, highlighting the early signs of synergy with checkpoint inhibitors. IMGS-101 is being developed as a hypoxia-reversal agent aimed at conditioning tumours to respond to checkpoint inhibition. Balstilimab and Zalifrelimab, both developed by the immuno-oncology company Agenus, are a fully human monoclonal immunoglobulin G1 targeting programmed cell death protein 1 (PD-1) and a cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), respectively. "ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
